Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33708
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nolan, Brendan James | - |
dc.contributor.author | Zwickl, Sav | - |
dc.contributor.author | Locke, Peter | - |
dc.contributor.author | Zajac, Jeffrey D | - |
dc.contributor.author | Cheung, Ada S | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-09-13T04:43:30Z | - |
dc.date.available | 2023-09-13T04:43:30Z | - |
dc.date.issued | 2023-09-05 | - |
dc.identifier.citation | JAMA Network Open 2023-09-05; 6(9) | en_US |
dc.identifier.issn | 2574-3805 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/33708 | - |
dc.description.abstract | Testosterone treatment is a necessary component of care for some transgender and gender-diverse individuals. Observational studies have reported associations between commencement of gender-affirming hormone therapy and improvements in gender dysphoria and depression, but there is a lack of data from randomized clinical trials. To assess the effect of testosterone therapy compared with no treatment on gender dysphoria, depression, and suicidality in transgender and gender-diverse adults seeking masculinization. A 3-month open-label randomized clinical trial was conducted at endocrinology outpatient clinics and primary care clinics specializing in transgender and gender-diverse health in Melbourne, Australia, from November 1, 2021, to July 22, 2022. Participants included transgender and gender-diverse adults aged 18 to 70 years seeking initiation of testosterone therapy. Immediate initiation of testosterone commencement (intervention group) or no treatment (standard care waiting list of 3 months before commencement). This design ensured no individuals would be waiting longer than the time to standard care. The primary outcome was gender dysphoria, as measured by the Gender Preoccupation and Stability Questionnaire. Secondary outcomes included the Patient Health Questionnaire-9 (PHQ-9) to assess depression and the Suicidal Ideation Attributes Scale (SIDAS) to assess suicidality. Questionnaires were undertaken at 0 and 3 months. The evaluable cohort was analyzed. Sixty-four transgender and gender-diverse adults (median [IQR] age, 22.5 [20-27] years) were randomized. Compared with standard care, the intervention group had a decrease in gender dysphoria (mean difference, -7.2 points; 95% CI, -8.3 to -6.1 points; P < .001), a clinically significant decrease in depression (ie, change in score of 5 points on PHQ-9; mean difference, -5.6 points; 95% CI, -6.8 to -4.4 points; P < .001), and a significant decrease in suicidality (mean difference in SIDAS score, -6.5 points; 95% CI, -8.2 to -4.8 points; P < .001). Resolution of suicidality assessed by PHQ-9 item 9 occurred in 11 individuals (52%) with immediate testosterone commencement compared with 1 (5%) receiving standard care (P = .002). Seven individuals reported injection site pain/discomfort and 1 individual reported a transient headache 24 hours following intramuscular administration of testosterone undecanoate. No individual developed polycythemia. In this open-label randomized clinical trial of testosterone therapy in transgender and gender-diverse adults, immediate testosterone compared with no treatment significantly reduced gender dysphoria, depression, and suicidality in transgender and gender-diverse individuals desiring testosterone therapy. ANZCTR Identifier: ACTRN1262100016864. | en_US |
dc.language.iso | eng | - |
dc.title | Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | JAMA Network Open | en_US |
dc.identifier.affiliation | Endocrinology | en_US |
dc.identifier.affiliation | Medicine (University of Melbourne) | en_US |
dc.identifier.affiliation | Equinox Gender Diverse Clinic, Thorne Harbour Health, Abbotsford, Victoria, Australia. | en_US |
dc.identifier.affiliation | Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia. | en_US |
dc.identifier.doi | 10.1001/jamanetworkopen.2023.31919 | en_US |
dc.type.content | Text | en_US |
dc.identifier.pubmedid | 37676662 | - |
dc.description.volume | 6 | - |
dc.description.issue | 9 | - |
dc.description.startpage | e2331919 | - |
dc.subject.meshtermssecondary | Testosterone/therapeutic use | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Endocrinology | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.